January 25, 2011

Bristol-Myers Squibb and sanofi-aventis announce U.S. FDA decision to grant pediatric exclusivity for PLAVIX®

 

Bristol-Myers Squibb and sanofi-aventis announce U.S. FDA decision to grant pediatric exclusivity for PLAVIX®

New York, New York and Paris, France – January 25, 2011 – Bristol-Myers Squibb Company (NYSE: BMY) and sanofi-aventis (EURONEXT: SAN, NYSE: SNY) today announced that the United States Food and Drug Administration (FDA) has granted the companies an additional sixmonth period of exclusivity to market PLAVIX® (clopidogrel bisulfate). Exclusivity for PLAVIX in the U.S. is now scheduled to expire on May 17, 2012.